Ingevity director granted 1,904-share equity award

NARWOLD KAREN G reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

NARWOLD KAREN G reported acquisition or exercise transactions in this Form 4 filing.

Ingevity Corp director receives equity award through a grant of 1,904 shares of common stock to Karen G. Narwold. The grant is reported at a price of $0.00 per share as a compensation-related award, not an open-market purchase, and increases her direct holdings to 18,900 shares.

The award represents restricted stock units granted under Ingevity Corporation's 2025 Omnibus Incentive Plan and is scheduled to vest in full on April 30, 2027. This filing records a routine equity-based compensation grant rather than a discretionary stock trade.

Insider Trade Summary

Grant/Award: 1,904 shares

Grant/Award 1 txn

Insider NARWOLD KAREN G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,904	$0.00	$0.00

Holdings After Transaction: Common Stock — 18,900 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock units pursuant to Ingevity Corporation's 2025 Omnibus Incentive Plan, which will vest in full on April 30, 2027.

Key Figures

Equity award size: 1,904 shares Grant price: $0.00 per share Post-grant holdings: 18,900 shares +1 more

4 metrics

Equity award size 1,904 shares Restricted stock units granted to director on April 30, 2026

Grant price $0.00 per share Reported grant price for restricted stock unit award

Post-grant holdings 18,900 shares Total Ingevity common shares held directly after the grant

RSU vesting date April 30, 2027 Restricted stock units vest in full on this date

Key Terms

restricted stock units, 2025 Omnibus Incentive Plan, Grant, award, or other acquisition

3 terms

restricted stock units financial

"Grant of restricted stock units pursuant to Ingevity Corporation's 2025 Omnibus Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2025 Omnibus Incentive Plan financial

"pursuant to Ingevity Corporation's 2025 Omnibus Incentive Plan, which will vest in full on April 30, 2027"

An omnibus incentive plan is a company-wide program that authorizes awards of pay tied to performance and retention—such as stock options, restricted shares, cash bonuses and other rewards—here labeled for the year it was adopted (2025). Investors care because it affects how much ownership can be issued, dilutes existing shareholders, and aligns executives’ and employees’ incentives with company goals, similar to giving team members a stake in the outcome.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ingevity (NGVT) report for Karen G. Narwold?

Ingevity reported that director Karen G. Narwold acquired 1,904 shares of common stock as an equity award. The shares were granted at $0.00 per share as part of compensation, not bought in the open market, and are structured as restricted stock units.

How many Ingevity (NGVT) shares does Karen G. Narwold hold after this grant?

After the award, Karen G. Narwold holds 18,900 shares of Ingevity common stock directly. This total reflects the new grant of 1,904 shares reported in the Form 4 and shows her updated post-transaction ownership position as disclosed in the filing.

What type of equity award did Ingevity (NGVT) grant to Karen G. Narwold?

Ingevity granted restricted stock units to director Karen G. Narwold under the company’s 2025 Omnibus Incentive Plan. The Form 4 notes these units convert into common stock as part of compensation, reflecting a routine long-term incentive award rather than a cash salary payment.

When do Karen G. Narwold’s Ingevity (NGVT) restricted stock units vest?

The restricted stock units granted to Karen G. Narwold are scheduled to vest in full on April 30, 2027. Vesting means the units become fully earned and settle into shares, encouraging longer-term alignment with shareholder interests during the vesting period.

Was Karen G. Narwold’s Ingevity (NGVT) transaction an open-market stock purchase?

No. The Form 4 classifies the transaction as a grant or award acquisition with a code “A,” not an open-market purchase. The 1,904 shares were granted at $0.00 per share as restricted stock units under the company’s incentive plan, reflecting compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 06:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NARWOLD KAREN G

(Last) (First) (Middle)

4920 O'HEAR AVE

SUITE 400

(Street)

NORTH CHARLESTON SOUTH CAROLINA 29405

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ingevity Corp [ NGVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		A		1,904(1)	A	$0	18,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units pursuant to Ingevity Corporation's 2025 Omnibus Incentive Plan, which will vest in full on April 30, 2027.

Remarks:

	Karen G. Narwold By: Mavis G. Huger as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)